Brain Cancer Market is expected to increase at a CAGR of 1.11% in the 7MM for the Study Period 2019-32, Says DelveInsight

July 18 18:55 2022
Brain Cancer Market is expected to increase at a CAGR of 1.11% in the 7MM for the Study Period 2019-32, Says DelveInsight

The Brain Cancer Market Insights report from DelveInsight provides a thorough understanding of the Brain Cancer Market size by treatment, epidemiology, emerging therapies, Brain Cancer market share of the various therapies, and the current and forecasted Brain Cancer Market size from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.


Brain Cancer: An Overview

A Brain Cancer, also known as an intracranial tumor, or central nervous system (CNS) tumor, is a group of diseases that share the common link of abnormal development of mass lesions in the brain, spinal cord, or its coverings. Symptoms of a Brain Cancer can be general or specific and vary depending upon the location of the Brain Cancer. A general symptom includes headaches, seizures, personality or memory changes, nausea or vomiting, fatigue, drowsiness, sleep problems, memory problems, and changes in the ability to walk or perform daily activities. While specific symptoms include pressure or headache near the tumor, loss of balance and difficulty with fine motor skills, changes in judgment, partial or complete loss of vision, changes in speech, hearing, memory, or emotional state.


Download a sample copy of Brain Cancer report offering-


Regions Covered in the Brain Cancer Market Report

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Key Takeaways from Brain Cancer Market Report

  • The marketed drugs in the Brain Cancer market landscape include Avastin (Genentech) and Temodar/Temodal (Merck). However, both the drugs have reached their patent expiration and their generics are floating in the market.
  • Generics have impacted the overall Brain Cancer market value, however, these are cost-effective and prove to be an advantage to patients.
  • The expected launch of potential Brain Cancer pipeline therapies, including Regorafenib, Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), Durvalumab, Tasadenoturev (DNX-2401) + Pembrolizumab, VAL-083 (Dianhydrogalactitol), ONC201, Selinexor (KPT-330), VBI-1901, Paxalisib (GDC-0084), AV-GBM-1, MDNA55, pp65-shLAMP DC with GM-CSF (ITI-1000), INO-5401+ INO-9012 + Cemiplimab (REGN2810), Eflornithine + Lomustine, Everolimus (RAD001) and Ad-RTS-hIL-12 + Veledimex ± Cemiplimab-Rwlc, is anticipated to add to the revenue generation in the Brain Cancer market in the coming years.
  • Out of all the emerging therapies, candidates that demonstrated promising results in the late- or phase III stage of clinical development include Ofranergene obadenovec (VB-111; VBL Therapeutics), Trans Sodium Crocetinate (Diffusion Pharmaceuticals), Eflornithine (Orbus Therapeutics), and Regorafenib (Bayer).
  • Orbus therapeutics’ Eflornithine is the only therapy under evaluation solely for recurrent anaplastic astrocytoma (AA) while the majority of other Brain Cancer therapies in the pipeline are being investigated for GBM.
  • The emerging Brain Cancer pipeline therapies also comprise budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex (Ziopharm) along with four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1, and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.
  • Discoveries of isocitrate dehydrogenase (IDH) mutation, co-deletion of the short arm of chromosome 1 and the long arm of chromosome 19 (1p19q), O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation, and histone H3-K27M mutation have led to a better understanding of the molecular aberrations associated with Brain Cancers.


Brain Cancer Epidemiology Insights

According to DelveInsight’s epidemiological analysis, the total Brain Cancer incident population in the 7MM was estimated to be 60,246 in 2020, which is expected to grow by 2030. Further, it was observed that males accounted for maximum Brain Cancer incident cases as compared to women.


Brain Cancer Epidemiology Segmentation in the 7MM

  • Total Primary Brain Cancer Incidence
  • Grade-specific Brain Cancer Incidence
  • Type-specific Brain Cancer Incidence
  • Gender-specific Brain Cancer Incidence
  • Age-specific Brain Cancer Incidence


Brain Cancer Treatment Market

Brain Cancers, especially High-grade gliomas are hard-to-treat tumors owing to the inability of available treatment regimens to remove the whole of the tumor due to their resistance to radiotherapy and chemotherapy. At the moment, there exists no ideal treatment. It is quite challenging to effectively develop one treatment that can target every tumor cell. Thus, the present Brain Cancer treatment landscape offers a combination of several of the available approaches including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery.

The Brain Cancer treatment market offers first-line treatment involving Surgery ± Radiation Therapy/ Chemotherapy, Temozolomide + Radiation Therapy (RT) or Radiation Alone- Maintenance therapy, and Temozolomide Monotherapy. The second-line treatment for Brain Cancer includes Bevacizumab Monotherapy, Bevacizumab Combination Therapy, Temozolomide (Both as Combination and Monotherapy), and Other Systemic Therapies (Concomitant and Adjuvant Chemotherapy agents). However, despite the availability of several combinations of therapies, the overall survival rate remains low and the chances or rates of recurrence are tremendously high. The Brain Cancer treatment market lacks an effective strategy to tackle Brain Cancers.  Thus, moving ahead, the Brain Cancer market is in dire need of therapies specific for the anaplastic form of tumors.


Brain Cancer Market

Key players such as Bayer, Diffusion Pharmaceuticals, VBL Therapeutics, AstraZeneca, DNAtrix, Kintara Therapeutics, Oncoceutics, KaryoPharm, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics, Inovio Pharmaceuticals, Orbus Therapeutics, Novartis, Ziopharm, and others are actively engaged in developing treatments and advancing Brain Cancer market.

In the 7MM, the United States accounted for the maximum Brain Cancer market share worth USD 986.0 Million in 2020 in comparison to EU5 (Italy, Germany, France, Spain, and the UK) and Japan, respectively. The market share is further expected to increase during the forecast period 2021-30.


Brain Cancer Therapies 

  • Trans Sodium Crocetinate
  • Regorafenib
  • Ofranergene obadenovec (VB-111)
  • Durvalumab
  • Tasadenoturev (DNX-2401) + Pembrolizumab
  • VAL-083 (Dianhydrogalactitol)
  • ONC201
  • Selinexor (KPT-330)
  • VBI-1901
  • Paxalisib (GDC-0084)
  • AV-GBM-1
  • MDNA55
  • pp65-shLAMP DC with GM-CSF (ITI-1000)
  • INO-5401+ INO-9012+Cemiplimab (REGN2810)
  • Eflornithine + Lomustine
  • Everolimus (RAD001)
  • Ad-RTS-hIL-12 + Veledimex ± Cemiplimab-Rwlc, and several others


Interested to know more about evolving novel therapeutic against?


Table of Content

  1. Key Insights
  2. Report Introduction
  3. Brain Cancer Market Overview at a Glance
  4. Executive Summary of Brain Cancer
  5. Key Events
  6. SWOT Analysis
  7. Disease Background and Overview
  8. Treatment
  9. National Comprehensive Cancer Network (NCCN) Guidelines for Central Nervous System Cancers (2020)
  10. Neurological and vascular complications of primary and secondary brain tumors: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up (2020)
  11. NICE Guidelines: Brain tumors (primary) and brain metastases in adults (2018)
  12. Treatment Algorithm
  13. Epidemiology and Patient Population
  14. Organizations contributing towards Brain Cancer
  15. Patient Journey
  16. Marketed Drugs
  17. Emerging Therapies
  18. Potential of Current Therapies and Emerging Therapies
  19. Brain Cancer: Seven Major Market Analysis
  20. KOL Views
  21. Market Drivers
  22. Market Barriers
  23. Unmet Needs
  24. Reimbursement and Market Access
  25. Appendix
  26. DelveInsight Capabilities
  27. Disclaimer
  28. About DelveInsight


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States